首页 | 本学科首页   官方微博 | 高级检索  
     


First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
Authors:Claus-Henning K?hne  Ralf Hofheinz  Laurent Mineur  Henry Letocha  Richard Greil  Josef Thaler  Eva Fernebro  Erick Gamelin  Lucy DeCosta  Meinolf Karthaus
Affiliation:(1) Department of Hematology and Oncology, Onkologie Klinikum Oldenburg, 26133 Oldenburg, Germany;(2) Day Treatment Centre at the Interdisciplinary Tumour Centre Mannheim, Universit?tsmedizin Mannheim, Mannheim, Germany;(3) Radiology and Oncology Centre, Institut Sainte-Catherine, Avignon, France;(4) Department of Oncology, County Hospital, V?ster?s, Sweden;(5) Third Medical Department, University Hospital Salzburg, Salzburg, Austria;(6) Department of Hematology and Medical Oncology, Klinikum Wels-Grieskirchen, Wels, Austria;(7) Department of Oncology, University Hospital, Lund, Sweden;(8) Department of Medical Oncology and Oncopharmacology, Centre Paul Papin, Angers, France;(9) Biostatistics, Amgen Limited, Uxbridge, UK;(10) Department of Hematology, Oncology and Palliative Medicine, Klinikum Neuperlach, Munich, Germany;(11) Department of Hematology, Oncology and Palliative Medicine, Klinikum Harlaching, Munich, Germany
Abstract:

Purpose  

Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号